Party Pills

This submission sets out what we believe can reasonably be concluded from current evidence about BZP and its harms, then analyses the potential impacts of the Bill. In developing this submission, we have consulted with a number of people and organisations within the alcohol and drug sector. We have also reviewed research findings on BZP. Our comments are influenced by the Drug Foundation’s guiding principles, including evidence based best practice and policy, and harm minimisation.

No one doubts the good intentions of the powers that be when they ban substances for the public good. But at what point do such bans become a paternalistic encroachment on individuals’ rights to choose? Anna Nuzum argues that party pill and other bans go too far, and lead to dangers that may be even worse than the problems they seek to address.

In 2004 Mr Anderton asked the Expert Advisory Committee on Drugs (EACD) to review recent New Zealand research on benzylpiperazine (BZP), the main ingredient in most party pills. The official EACD report was released by Mr Anderton on 20 December 2006. It recommended BZP be classified as C1 under the Misuse of Drugs Act alongside drugs such as cannabis. It is illegal to possess or sell Class C drugs.

This paper summarises recent research findings on BZP/party pills, and outlines the current legislative status of BZP. It is being made available to assist organisations or people wanting to make submissions on the proposal to reclassify BZP and its analogues.